Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus FOLFIRI as first-line therapy in metastatic colorectal cancer
2006-006739-36Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Amgen. Primary endpoint: Objective response rate (ORR). Started Feb 2007; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-006739-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006739-36.